Detalhe da pesquisa
1.
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
Future Oncol
; 20(16): 1069-1077, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38214149
2.
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Gastric Cancer
; 25(3): 598-608, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35050442
3.
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Gastroenterology
; 156(6): 1731-1741, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30738047
4.
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(3): 408-419, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30738780
5.
Identification and characterisation of carnostatine (SAN9812), a potent and selective carnosinase (CN1) inhibitor with in vivo activity.
Amino Acids
; 51(1): 7-16, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29922921
6.
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Lancet Oncol
; 16(8): 937-48, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26184520
7.
Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Onco Targets Ther
; 17: 267-280, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38567193
8.
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
Cancer Discov
; 13(8): 1802-1813, 2023 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269344
9.
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Eur J Cancer
; 153: 142-152, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34157616
10.
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.
Clin Cancer Res
; 24(19): 4650-4661, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29950351
11.
Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.
Oncotarget
; 8(63): 107096-107108, 2017 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29291014
12.
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Target Oncol
; 12(1): 97-109, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27975152
13.
Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase.
J Biol Chem
; 278(8): 6521-31, 2003 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-12473676